Juvenile Inflammatory Rheumatism (JIR) Cohorte

NCT ID: NCT02377245

Last Updated: 2023-06-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

15000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The JIR-cohort has to be filled by an authorized investigator during or after the consultation. Each patient much be followed at least once a year.

Different data are requested in the JIR-cohort: diagnosis, treatment, adverse events and outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Juvenile Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Juvenile Inflammatory Rheumatism

Juvenile Inflammatory Rheumatism patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with juvenile inflammatory diseases
* Age at onset up to 18 years old
* Consent according national codes of ethics and current laws

Exclusion Criteria

* Non-consent from patients and/or legal representative
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role collaborator

Versailles Hospital

OTHER

Sponsor Role collaborator

Tenon Hospital, Paris

OTHER

Sponsor Role collaborator

Bicetre Hospital

OTHER

Sponsor Role collaborator

University of Lausanne Hospitals

OTHER

Sponsor Role collaborator

University Hospital Muenster

OTHER

Sponsor Role collaborator

Fondation Rhumatismes-Enfants-Suisse

UNKNOWN

Sponsor Role collaborator

Michaël Hofer

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michaël Hofer

Head of Pediatric Rheumatology unit

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Hofer

Role: STUDY_DIRECTOR

University of Lausanne Hospitals

Véronique Hentgen

Role: STUDY_DIRECTOR

Versailles Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Reine Fabiola

Brussels, , Belgium

Site Status

CHU Charleroi

Charleroi, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

CHC Liège

Liège, , Belgium

Site Status

CHR Citadelle

Liège, , Belgium

Site Status

CHU Belfort

Belfort, , France

Site Status

CHRU Besançon

Besançon, , France

Site Status

Hôpital Pellegrin enfants

Bordeaux, , France

Site Status

CHRU Brest

Brest, , France

Site Status

Hôpital Femme Mère Enfant

Bron, , France

Site Status

CHU Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

CHU de Grenoble

Grenoble, , France

Site Status

Hôpital Bicêtre

Le Kremlin-Bicêtre, , France

Site Status

CHRU Lille

Lille, , France

Site Status

Hôpital Nord Marseille

Marseille, , France

Site Status

CHU Arnaud de Villeneuve

Montpellier, , France

Site Status

Centre hospitalier de Mulhouse

Mulhouse, , France

Site Status

CHU Nantes

Nantes, , France

Site Status

Nice CHU - Lenval

Nice, , France

Site Status

CHU Nimes

Nîmes, , France

Site Status

Hôpital necker Enfants Malade

Paris, , France

Site Status

Hôpital Robert Debré

Paris, , France

Site Status

Hôpital Tenon

Paris, , France

Site Status

CHU Reims

Reims, , France

Site Status

CHU Rennes

Rennes, , France

Site Status

CHU St-Etienne

Saint-Etienne, , France

Site Status

Hôpital de Hautepierre

Strasbourg, , France

Site Status

Hôpital des enfants

Toulouse, , France

Site Status

CHU Tours

Tours, , France

Site Status

Hôpital André Mignot

Versailles, , France

Site Status

University Hospital Muenster

Münster, , Germany

Site Status

Hôpital Ibnou Rochd

Casablanca, , Morocco

Site Status

CHUV

Lausanne, Canton of Vaud, Switzerland

Site Status

Kantonsspital Aarau

Aarau, , Switzerland

Site Status

Kinderspital Basel

Basel, , Switzerland

Site Status

Universitäts-Augenklinik Basel

Basel, , Switzerland

Site Status

Ospedale Regionale di Bellinzona e valli

Bellinzona, , Switzerland

Site Status

Kantonspital Graubunden

Chur, , Switzerland

Site Status

Hôpital Ophtalmique

Lausanne, , Switzerland

Site Status

Kinderspital Luzern

Lucerne, , Switzerland

Site Status

Ospedale Regionale di Lugano

Lugano, , Switzerland

Site Status

Ostschweizer Kinderspital St-Gallen

Sankt Gallen, , Switzerland

Site Status

Klinik für Rheumatologie und internistische Rehabilitation

Valens, , Switzerland

Site Status

Kantonspital Winterthur

Winterthur, , Switzerland

Site Status

Kinderspital Zürich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium France Germany Morocco Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, Bensaid P, Pichard S, Kouider H, Morelle G, Craiu I, Pondarre C, Deho A, Maroni A, Oualha M, Amoura Z, Haroche J, Chommeloux J, Bajolle F, Beyler C, Bonacorsi S, Carcelain G, Kone-Paut I, Bader-Meunier B, Faye A, Meinzer U, Galeotti C, Melki I. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020 Aug;79(8):999-1006. doi: 10.1136/annrheumdis-2020-217960. Epub 2020 Jun 11.

Reference Type DERIVED
PMID: 32527868 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.jircohorte.org

Official jir-cohorte project webpage

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JIR-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Abatacept in Juvenile Dermatomyositis
NCT02594735 COMPLETED PHASE4